




Date: 15 July 2010

Title: **Northeast Region Winner BVCA Portfolio Company Management Awards 2010 – Venture Backed Capital Team of the Year**

On 14 July 2010 the BVCA announced that Neoss Limited had won the Northeast Region Venture Backed Capital Team of the Year 2010.

Michael J Dormer, Executive Chairman, commented "this award is not just for the Neoss Management team but a result of the hard work of all the staff at Neoss and its Distributors that have helped to make Neoss what it is today. I look forward to continuing to work with everyone in the Neoss family in the coming months and years and to the Company's continued success. I would also like to thank all our investors and customers without whom we would not be a success".



NEOSS CONTACT:

Mike Dormer

Executive Chairman mdormer@neoss.com

Tel: +44 (0)1423 817733

Guy Leaver

Chief Financial Officer guy.leaver@neoss.com

Tel: +44 (0)1423 817733

NOTES FOR EDITORS:

Neoss' objective is to advance the science of dental implant treatment and build a significant and profitable dental implant company recognised for leading innovation, customer focus and ethical principles.

Dental implants are titanium screws that are used to anchor a single dental crown or a number of artificial teeth as a bridge or a denture. They act as alternatives to traditional crowns, bridges, dentures and false teeth. The largest markets are Europe and the US which represent 48% and 24% of the global market. It is a highly attractive market with leading companies achieving gross margins in excess of 80%. The market up to 2007 was growing at 15% per year but slowed in 2008 and 2009 as a result of the global financial crisis. The Neoss dental implant system is the most efficient dental implant system in the market. It combines market-leading functionality for the patient with the lowest level of complexity available for the Surgeon. In essence the system does more things, more simply and more economically than the current market leaders, and it does all those things at least as well as its competitors.

Recent product launches include:

Neoss ProActive implant, an implant building on the proven design of the Neoss Bimodal Implant, is a Hydrophilic implant. The rapid wetting of the implant surface enhances protein aggregation and can accelerate fibrin network formation. Studies show the, patent pending, etched and blasted ProActive implant surface stimulates bone to form more rapidly and with a greater strength at the implant interface.

The Company founded in 2000 by CEO, Prof. Neil Meredith and CTO, Fredrik Engman is head quartered in the Harrogate, in the United Kingdom and has operations in USA, Germany, Austria, Italy, Sweden, Australia and New Zealand and is represented in Switzerland, Ireland, Croatia, Poland, Turkey, Japan, Thailand and Taiwan by exclusive distributors.

Further information is available at www.neoss.com